• E-mail :[email]
  • Phone : 0380393468
  • Location : Dijon, France
Last update 2017-03-08 10:54:49.326

Olivier Micheau PhD, Molecular and Cellular Biology : Expertise in TNF Signaling

Course and current status

Research :

  • Since 2015: Research director (DR2, INSERM), INSERM U866,  UFR Science de Santé, 7 Bd Jeanne d’Arc; F21000 Dijon,  France. 
  • Since 2015 : Member of the Fondation ARC scientific council CN4
  • Since 2012 : Member of the INSERM scientific council CSS3
  • Since 2012 : Associate Editor British Journal of Pharmacology
  • Since 2003 : Chargé de Recherche (Ass. Professor), INSERM U866 (former U517), Faculty of Medicine, 7 Bd Jeanne d’Arc; F21000 Dijon, France. 
  • 2008- 2012  INSERM Interface contract with Hospitals (Translational research with the CGFL cancer center). 
  • 1999-2003:    Post-doctoral Research Scientist, Institute of Biochemistry,   Lausanne, Switzerland in Jürg Tschopp’s laboratory.
  • 1995-1999:     PhD in Molecular And Cellular Biology, INSERM U517, University of Burgundy, Dijon, France – Supervised by: Dr Marie Thérèse Dimanche-Boitrel. 

Education :

  • 2005:              Habilitation à diriger des recherches (HDR, required to supervise PhDs), University of Burgundy, Dijon, France.
  • 1994-1995:     DEA (Master 2nd year) INSERM U517, Dijon University of Burgundy, Dijon, France.
  • 1992-1993:      Maîtrise de Biologie Cellulaire : Génétique (1st Year of Master Cellular biology and genetics), Paul Sabatier University, Toulouse, France.
  • 1991-1992:      Bsc (Bachelor of Science) Biochemistry, University of Central Lancashire, Preston, UK.

Scientific summary

My research interests, centered on TNF receptor members, have led to several important discoveries, including cross-talks between TNF receptors such as Fas and conventional chemotherapeutic drugs (Micheau et al. 1997and 1999) or elucidation of the molecular mechanisms underlying TNFR1 pleiotropic signaling (Micheau et al, 2001 and 2003)

My actual interest is to further understand TRAIL signal transduction in order to optimize TRAIL-based antitumor therapeutic strategies (Mérino et al. 2006; Morizot et al. 2011; Jacquemin et al. 2012; Zakaria et al. 2015; Dufoura et al. 2017;Dufourb et al. 2017).


Selected publications

  • Micheau, O., and Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. 2003 Cell 114, 181-190.
  • Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., and Micheau, O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. 2016 Mol Cell Biol 26, 7046-7055.
  • Morizot, A., Merino, D., Lalaoui, N., Jacquemin, G., Granci, V., Iessi, E., Lanneau, D., Bouyer, F., Solary, E., Chauffert, B., Saas, P., Garrido, C., Micheau, O. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. 2011 Cell Death Differ18, 700-711.
  • Zakaria AB, Picaud F, Rattier T, Pudlo M, Saviot L, Chassagnon R, Lherminier J, Gharbi T, Herlem G* and Micheau O*. Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing. 2015 Nano Letters 15(2):891-895.
  • Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, and Micheau O. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. 2017 Oncotarget  8(6):9974-9985.
  • Dufour F*, Rattier T*, Shirley S*, Picarda G, Constantinescu AA, Morlé A, Zakaria AB, Marcion G, Causse S, Szegezdi E, Zajonc DM, Seigneuric R, Guichard G, Gharbi T, Picaud F, Herlem G, Garrido C, Schneider P, Benedict CA and Micheau O. N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. 2017 Cell Death Differ.  24(3), 500-510.
  •  

     

    Image d’exemple